目的 研究芪苈强心胶囊联合托伐普坦片治疗中度充血性心力衰竭的临床效果。方法 选取2017年1月-2018年1月安阳地区医院收治的中度充血性心力衰竭患者80例为研究对象，采用随机数字表法随机分为对照组和治疗组，每组各40例。对照组口服托伐普坦片，起始剂量为15 mg，服药24 h后，根据血清钠浓度调整剂量，最大用药剂量为60 mg，当血钠浓度>145 mmol/L时停用。治疗组在对照组治疗的基础上温水口服芪苈强心胶囊，4粒/次，3次/d。两组患者均连续服用7 d。观察两组的临床疗效，比较两组的血清Na⁺、K⁺浓度、体质量、心功能和炎性因子水平。结果 治疗后，对照组和治疗组的总有效率分别为75.00%、92.50%，两组比较差异有统计学意义（P<0.05）。治疗后，两组Na⁺浓度显著提高，而体质量显著减轻，同组治疗前后比较差异有统计学意义（P<0.05）；且治疗后治疗组体质量显著低于对照组，两组比较差异有统计学意义（P<0.05）。治疗后，两组每搏量（SV）、心排血量（CO）和左心室射血分数（LVEF）值均显著升高，同组治疗前后比较差异有统计学意义（P<0.05）；且治疗后治疗组心功能指标水平均显著高于对照组，两组比较差异有统计学意义（P<0.05）。治疗后，两组血浆一氧化氮（NO）和血清肿瘤坏死因子-α（TNF-α）、白细胞介素-6（IL-6）水平均显著降低，同组治疗前后比较差异有统计学意义（P<0.05）；且治疗后治疗组各炎性因子水平显著低于对照组，两组比较差异有统计学意义（P<0.05）。结论 芪苈强心胶囊联合托伐普坦片治疗中度充血性心力衰竭具有较好的临床疗效，能调节机体电解质平衡，改善心功能，安全性较好，具有一定的临床推广应用价值。

Objective To study the clinical effects of Qili Qiangxin Capsules combined with Tolvaptan Tablets in treatment of moderate congestive heart failure.Methods Patients (80 cases) with moderate congestive heart failure in Anyang District Hospital from January 2017 to January 2018 were randomly divided into control and treatment groups, and each group had 40 cases. Patients in the control group were po administered with Tolvaptan Tablets, starting dosage 15 mg, and after 24 h, the dosage was adjusted according to the serum sodium concentration. The maximum dosage was 60 mg. When the serum sodium concentration was higher than 145 mmol/L, the dosage was discontinued. Patients in the treatment group were po administered with Qili Qiangxin Capsules on the basis of the control group, 4 grains/time, three times daily. Patients in two groups were treated for 7 d. After treatment, the clinical efficacies were evaluated, and serum concentration of Na⁺ and K⁺, body mass, cardiac function, inflammatory factors in two groups were compared.Results After treatment, the clinical efficacies in the control and treatment groups were 75.00% and 92.50%, respectively, and there was difference between two groups (P<0.05). After treatment, the Na⁺ concentration in two groups were significantly increased, but the body mass in two groups significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the body mass in the treatment group were significantly lower than that in the control group, with significant difference between two groups (P<0.05). After treatment, SV, CO, and LVEF in two groups were significantly increased, and the difference was statistically significant in the same group (P<0.05). And the cardiac function indexes in the treatment group were significantly higher than those in the control group, with significant difference between two groups (P<0.05). After treatment, the levels of NO, TNF-α, and IL-6 in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the inflammatory factors levels in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P<0.05).Conclusion Qili Qiangxin Capsules combined with Tolvaptan Tablets has clinical curative effect in treatment of moderate congestive heart failure, can regulate electrolyte balance, and improve cardiac function, with good safety, which has a certain clinical application value.